Emmaus Life Sciences Reports 25% Revenue Drop, Widened Net Loss in 2025
Summary
Emmaus Life Sciences reported its 2025 annual financial results, revealing a significant 25% decline in net revenues to $12.5 million, primarily due to generic competition for its sickle cell disease treatment, Endari, in the U.S. Despite a 34% reduction in operating expenses leading to a modest income from operations of $0.2 million (compared to a $1.9 million loss in 2024), the company's net loss widened to $7.2 million, or $0.11 per share, from $6.5 million in the prior year, largely due to increased other expenses. This report highlights the severe pressure from generic competition on its core product. Traders will be closely watching the implementation of the new U.S. license and distribution arrangement with NeoImmuneTech, expected in Q2 2026, and the company's ability to drive growth in international markets to offset domestic challenges.
At the time of this announcement, EMMA was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $977.3K. The 52-week trading range was $0.00 to $0.05. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.